Handelsinvest Investeringsforvaltning Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Handelsinvest Investeringsforvaltning trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 34.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,518 shares of the medical research company’s stock after selling 788 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in Charles River Laboratories International were worth $411,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CRL. LPL Financial LLC lifted its position in Charles River Laboratories International by 14.5% during the third quarter. LPL Financial LLC now owns 38,349 shares of the medical research company’s stock valued at $7,498,000 after buying an additional 4,856 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Charles River Laboratories International by 8.8% in the third quarter. Tower Research Capital LLC TRC now owns 3,604 shares of the medical research company’s stock valued at $706,000 after acquiring an additional 292 shares in the last quarter. Bank of Nova Scotia raised its holdings in Charles River Laboratories International by 24.2% in the third quarter. Bank of Nova Scotia now owns 2,634 shares of the medical research company’s stock valued at $516,000 after acquiring an additional 513 shares in the last quarter. Gotham Asset Management LLC raised its holdings in Charles River Laboratories International by 13.0% in the third quarter. Gotham Asset Management LLC now owns 16,077 shares of the medical research company’s stock valued at $3,151,000 after acquiring an additional 1,844 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its holdings in Charles River Laboratories International by 222.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 12,004 shares of the medical research company’s stock valued at $2,353,000 after acquiring an additional 8,285 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Robert W. Baird cut their price target on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. TD Cowen lowered their target price on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research note on Monday, May 13th. The Goldman Sachs Group initiated coverage on shares of Charles River Laboratories International in a research note on Thursday, June 6th. They set a “buy” rating and a $290.00 target price for the company. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Finally, Mizuho initiated coverage on shares of Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 target price for the company. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $254.50.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

CRL stock opened at $201.42 on Thursday. The company has a market capitalization of $10.38 billion, a P/E ratio of 23.70, a PEG ratio of 1.95 and a beta of 1.38. The company has a 50-day simple moving average of $218.04 and a 200 day simple moving average of $232.13. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.05 by $0.22. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).